http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100694994-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-535 |
| filingDate | 2005-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100694994-B1 |
| titleOfInvention | Human granulocyte colony forming factor homologue |
| abstract | The present invention relates to a novel physiologically active protein produced for enhancing the in vivo persistence of human granulocyte colony forming factors, and to a human granulocyte colony forming factor homologue which combines a polypeptide and a polyethylene glycol (PEG) polymer which is not a polypeptide component. . In the present invention, it is possible to bind polyethylene glycol to a specific site of the polypeptide while selecting a site that does not affect the activity of the protein, perform the modification of the amino acid for this portion to cysteine, and the polyethylene bond at this modified position It is characterized by the above-mentioned. The present invention also provides a pharmaceutical composition comprising the homolog, a gene encoding them, a primer for changing an amino acid sequence, and the like.n n n n Human granulocyte colony forming factor, persistence in body, polyethylene glycol, PEG, cysteine substitution |
| priorityDate | 2005-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.